Shire (LON:SHP) Rating Reaffirmed
Shire (LON:SHP) just had their share rating of a ‘”Outperform”‘ issued by research analysts at Bernstein, who now has a GBX 6000 target PPS on the 25.09 billion GBP market cap company or a 41.98% upside potential. This key information was shown in a comprehensive report on Monday, 14 December.
From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.97. The mean of all analyst targets is GBX 89.82 with a 27.19% above today’s (GBX 4236) stock price. Shire PLC was the topic of 83 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 9 with “Neutral” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. J.P. Morgan maintained SHP stock in a recent report from December 4 with “Overweight” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.
Approximately 309,145 shares of stock traded hands. Shire PLC (LON:SHP) has declined 20.17% since May 15, 2015 and is downtrending. It has underperformed by 15.75% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of 25.09 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 12.47 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.